Safety and feasibility of motexafin gadolinium administration with whole brain radiation therapy and stereotactic radiosurgery boost in the treatment of ≤6 brain metastases: a multi-institutional phase II trial

[1]  K. Hess,et al.  Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. , 2009, The Lancet. Oncology.

[2]  A. Holmgren,et al.  Mechanism of inhibition of ribonucleotide reductase with motexafin gadolinium (MGd). , 2009, Biochemical and biophysical research communications.

[3]  J. Uhm.  Motexafin gadolinium combined with prompt whole brain radiotherapy prolongs time to neurologic progression in non–small-cell lung cancer patients with brain metastases: results of a phase III trial , 2009 .

[4]  M. Mehta,et al.  Motexafin gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: a Children's Oncology Group phase I study. , 2008, Neuro-oncology.

[5]  R. Amato,et al.  Motexafin gadolinium for the treatment of metastatic renal cell carcinoma: phase II study results. , 2008, Clinical genitourinary cancer.

[6]  W. Curran,et al.  Results of the phase I dose-escalating study of motexafin gadolinium with standard radiotherapy in patients with glioblastoma multiforme. , 2007, International journal of radiation oncology, biology, physics.

[7]  Y. Oh,et al.  Phase I Trial of Motexafin Gadolinium in Combination with Docetaxel and Cisplatin for the Treatment of Non-small Cell Lung Cancer , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[8]  H. Shirato,et al.  Neurocognitive function of patients with brain metastasis who received either whole brain radiotherapy plus stereotactic radiosurgery or radiosurgery alone. , 2007, International journal of radiation oncology, biology, physics.

[9]  M. Mehta,et al.  Regression after whole-brain radiation therapy for brain metastases correlates with survival and improved neurocognitive function. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Hiroki Shirato,et al.  Stereotactic Radiosurgery Plus Whole-Brain Radiation Therapy vs Stereotactic Radiosurgery Alone for Treatment of Brain Metastases: A Randomized Controlled Trial , 2007 .

[11]  A. Holmgren,et al.  Motexafin Gadolinium, a Tumor-selective Drug Targeting Thioredoxin Reductase and Ribonucleotide Reductase* , 2006, Journal of Biological Chemistry.

[12]  D. Kondziolka,et al.  Stereotactic radiosurgery for four or more intracranial metastases. , 2005, International journal of radiation oncology, biology, physics.

[13]  Jeffry R. Alger,et al.  MRI measurement of the uptake and retention of motexafin gadolinium in glioblastoma multiforme and uninvolved normal human brain , 2006, Journal of Neuro-Oncology.

[14]  J. Hacia,et al.  Motexafin gadolinium and zinc induce oxidative stress responses and apoptosis in B-cell lymphoma lines. , 2005, Cancer research.

[15]  J. Hacia,et al.  Motexafin gadolinium disrupts zinc metabolism in human cancer cell lines. , 2005, Cancer research.

[16]  G. Bepler,et al.  Ribonucleotide reductase M1 gene promoter activity, polymorphisms, population frequencies, and clinical relevance. , 2005, Lung cancer.

[17]  Maria Werner-Wasik,et al.  Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial , 2004, The Lancet.

[18]  M. Sharr.  Intracranial metastases , 2004, Journal of Neuro-Oncology.

[19]  W. Curran,et al.  Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Christiane,et al.  WORLD MEDICAL ASSOCIATION DECLARATION OF HELSINKI: Ethical Principles for Medical Research Involving Human Subjects , 2001, Journal of postgraduate medicine.

[21]  J. Sessler,et al.  Redox cycling by motexafin gadolinium enhances cellular response to ionizing radiation by forming reactive oxygen species. , 2001, International journal of radiation oncology, biology, physics.

[22]  B. Sikic,et al.  Motexafin gadolinium: a redox active drug that enhances the efficacy of bleomycin and doxorubicin. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[23]  H. Thaler,et al.  Effects of Motexafin gadolinium on tumor metabolism and radiation sensitivity. , 2001, International journal of radiation oncology, biology, physics.

[24]  S. Eckstein.  Ethical principles for medical research involving human subjects. , 2001, European journal of emergency medicine : official journal of the European Society for Emergency Medicine.

[25]  N. N. Available.  World medical association declaration of Helsinki , 2000, Chinese Journal of Integrative Medicine.

[26]  L Souhami,et al.  Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05. , 2000, International journal of radiation oncology, biology, physics.

[27]  J A Koutcher,et al.  In vivo animal studies with gadolinium (III) texaphyrin as a radiation enhancer. , 1999, International journal of radiation oncology, biology, physics.

[28]  L D Lunsford,et al.  Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases. , 1999, International journal of radiation oncology, biology, physics.

[29]  D. Vanel,et al.  Phases IB and II multidose trial of gadolinium texaphyrin, a radiation sensitizer detectable at MR imaging: preliminary results in brain metastases. , 1999, Radiology.

[30]  D I Rosenthal,et al.  A phase I single-dose trial of gadolinium texaphyrin (Gd-Tex), a tumor selective radiation sensitizer detectable by magnetic resonance imaging. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[31]  L Gaspar,et al.  Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. , 1997, International journal of radiation oncology, biology, physics.

[32]  Roy A. Patcheil.  Metastatic brain tumors. , 1995 .

[33]  R. Gelber,et al.  The palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. , 1980, International journal of radiation oncology, biology, physics.

[34]  E. Lang,et al.  METASTATIC BRAIN TUMORS. RESULTS OF SURGICAL AND NONSURGICAL TREATMENT. , 1964, The Surgical clinics of North America.

[35]  W. Pagel.  Chronic Disseminated Tuberculosis , 1937, British medical journal.